TECH BIO-TECHNE Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECH

Price (delayed)

$365.49

Market cap

$14.34B

P/E Ratio

63.56

Dividend/share

$1.28

EPS

$5.75

Enterprise value

$14.51B

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's ...

Highlights
TECH's P/E is 37% below its last 4 quarters average of 100.6 and 4.6% below its 5-year quarterly average of 66.1
The gross profit rose by 28% YoY and by 4.7% QoQ
BIO-TECHNE's debt has increased by 12% YoY but it has decreased by 7% QoQ
The quick ratio has declined by 17% year-on-year and by 7% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.bio-techne.com/
Peers: TMO BDX BIO STEM

Key stats

What are the main financial stats of TECH
Market
Shares outstanding
39.23M
Market cap
$14.34B
Enterprise value
$14.51B
Valuations
Price to earnings (P/E)
63.56
Price to book (P/B)
8.38
Price to sales (P/S)
13.33
EV/EBIT
57.32
EV/EBITDA
41.1
EV/Sales
13.48
Earnings
Revenue
$1.08B
EBIT
$253.06M
EBITDA
$352.93M
Free cash flow
$301.92M
Per share
EPS
$5.75
Free cash flow per share
$7.69
Book value per share
$43.64
Revenue per share
$27.41
TBVPS
$23.45
Balance sheet
Total assets
$2.3B
Total liabilities
$586.57M
Debt
$327.23M
Equity
$1.71B
Working capital
$426.27M
Liquidity
Debt to equity
0.19
Current ratio
3.55
Quick ratio
2.6
Net debt/EBITDA
0.47
Margins
EBITDA margin
32.8%
Gross margin
68%
Net margin
20.9%
Operating margin
26.4%
Efficiency
Return on assets
9.9%
Return on equity
13.6%
Return on invested capital
28.4%
Return on capital employed
11.9%
Return on sales
23.5%
Dividend
Dividend yield
0.35%
DPS
$1.28
Payout ratio
22.3%

TECH stock price

How has the BIO-TECHNE stock price performed over time
Intraday
0.75%
1 week
5.44%
1 month
-0.14%
1 year
-21.18%
YTD
-29.35%
QTD
5.44%

Financial performance

How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.08B
Gross profit
$732.09M
Operating income
$284.6M
Net income
$225.49M
Gross margin
68%
Net margin
20.9%
The company's operating income rose by 37% YoY and by 8% QoQ
The gross profit rose by 28% YoY and by 4.7% QoQ
The revenue has grown by 27% YoY and by 4.5% from the previous quarter
The net income has increased by 22% YoY and by 7% from the previous quarter

Growth

What is BIO-TECHNE's growth rate over time

Valuation

What is BIO-TECHNE stock price valuation
P/E
63.56
P/B
8.38
P/S
13.33
EV/EBIT
57.32
EV/EBITDA
41.1
EV/Sales
13.48
TECH's P/E is 37% below its last 4 quarters average of 100.6 and 4.6% below its 5-year quarterly average of 66.1
TECH's EPS is up by 20% year-on-year and by 7% since the previous quarter
The stock's price to book (P/B) is 25% less than its last 4 quarters average of 11.1 but 12% more than its 5-year quarterly average of 7.4
BIO-TECHNE's equity has increased by 11% YoY
The price to sales (P/S) is 28% lower than the last 4 quarters average of 18.4 but 5% higher than the 5-year quarterly average of 12.6
The revenue has grown by 27% YoY and by 4.5% from the previous quarter

Efficiency

How efficient is BIO-TECHNE business performance
BIO-TECHNE's ROIC has increased by 14% YoY and by 7% from the previous quarter
TECH's return on assets is up by 10% year-on-year and by 5% since the previous quarter
TECH's return on sales is down by 10% year-on-year but it is up by 5% since the previous quarter
BIO-TECHNE's return on equity has increased by 9% YoY and by 3.8% QoQ

Dividends

What is TECH's dividend history
Dividend details
DPS
$1.28
Dividend yield
0.35%
Payout ratio
22.3%
Recent dividends

Financial health

How did BIO-TECHNE financials performed over time
The quick ratio has declined by 17% year-on-year and by 7% since the previous quarter
TECH's current ratio is down by 14% YoY and by 7% from the previous quarter
BIO-TECHNE's debt is 81% lower than its equity
BIO-TECHNE's debt has increased by 12% YoY but it has decreased by 7% QoQ
BIO-TECHNE's equity has increased by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.